Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Canopy Growth is a Canadian cannabis producer operating cultivation facilities in Ontario and Saskatchewan, with distribution across Canadian provinces and limited international medical cannabis exports. The company has undergone significant restructuring since 2020, divesting US assets and closing unprofitable facilities while burning cash at approximately $200M annually. Trading at 0.7x book value with negative operating cash flow, the stock reflects deep distress pricing as the company navigates oversupplied Canadian recreational markets and regulatory uncertainty around US federal legalization.
Canopy cultivates cannabis at indoor and greenhouse facilities, processes into finished goods (flower, oils, edibles, beverages), and sells through provincial wholesale channels in Canada or direct to medical patients. Pricing power has collapsed since 2019 due to oversupply - wholesale prices declined from $7-8/gram to $2-3/gram by 2024. The company's 29.6% gross margin reflects commodity economics with limited differentiation. Revenue has declined 9.5% YoY as the company exits unprofitable SKUs and focuses on higher-margin segments. Operating leverage is negative given fixed cultivation costs and underutilized capacity.
US federal cannabis legalization or rescheduling developments - potential market access to $30B+ US market drives speculative positioning
Canadian market pricing trends - wholesale cannabis prices per gram directly impact gross margins and path to profitability
Cash burn rate and liquidity runway - company has burned through $2B+ since 2020, requiring equity raises or asset sales
Quarterly revenue trajectory and market share in Canadian recreational segment - indicates competitive positioning versus Aurora, Tilray, Hexo
Strategic partnerships or M&A activity - consolidation potential in fragmented cannabis sector
Canadian market oversupply and commoditization - licensed cultivation capacity exceeds demand by 3-4x, sustaining price pressure and margin compression across the industry with limited path to supply rationalization
US federal prohibition - Canopy divested US operations in 2023 but remains locked out of the $30B US market while US-domiciled MSOs (Curaleaf, Trulieve, Green Thumb) build scale advantages
Regulatory uncertainty around product formats - Health Canada restrictions on THC limits, packaging, and marketing constrain product innovation and brand differentiation versus illicit market
Provincial distribution monopolies - government-controlled wholesale channels in most provinces limit direct customer relationships and pricing power
Market share erosion to lower-cost producers - competitors like Hexo and Aurora have achieved sub-$1/gram production costs versus Canopy's estimated $1.50-2.00/gram through automation and scale
Illicit market competition - illegal cannabis estimated at 30-40% of Canadian consumption, offering lower prices without excise taxes and regulatory compliance costs
US MSO competitive positioning - if federal legalization occurs, well-capitalized US operators with established retail networks could enter Canada or acquire distressed Canadian LPs at depressed valuations
Liquidity runway concerns - with $200M annual cash burn and current ratio of 5.34x suggesting approximately $300-400M in liquid assets, the company has 18-24 months of runway without additional financing
Equity dilution risk - negative cash flow necessitates periodic equity raises, diluting existing shareholders; share count has increased substantially since 2020
Asset impairment exposure - carrying value of cultivation facilities, brands, and goodwill may require further writedowns if profitability targets are not achieved
Contingent liabilities from facility closures and restructuring - ongoing costs from lease obligations and severance from shuttered operations
moderate - Cannabis demonstrates mixed cyclical characteristics. Recreational demand shows modest correlation with discretionary spending and consumer sentiment, particularly for premium products and edibles. Medical cannabis exhibits counter-cyclical tendencies as patients prioritize therapeutic use regardless of economic conditions. However, the Canadian market is mature and saturated, limiting GDP sensitivity. The company's distressed financial position makes it more sensitive to capital market conditions than underlying cannabis demand.
High sensitivity through multiple channels. Rising rates increase financing costs on the company's debt obligations and make equity raises more dilutive, critical given negative free cash flow of $200M annually. Higher rates compress valuation multiples for unprofitable growth companies - cannabis stocks traded at 10-15x sales in 2018-2019 versus 1-2x currently. Additionally, elevated rates reduce speculative risk appetite that drives cannabis sector momentum. The company's survival depends on access to capital markets, making rate policy a primary concern.
Moderate credit exposure. While Canopy has relatively low debt/equity of 0.36x following deleveraging, the company's negative operating cash flow creates refinancing risk. Credit market tightening would impair ability to raise capital through convertible debt or credit facilities. The cannabis sector faces structural credit constraints due to US federal illegality limiting banking relationships and institutional participation. Tightening credit conditions would accelerate consolidation pressure and potentially force distressed asset sales.
momentum/speculative - The stock attracts retail traders and speculative investors betting on US federal legalization catalysts or sector rotation into cannabis. Deep value investors may see distressed opportunity at 0.7x book value, but negative cash flow and dilution risk deter traditional value funds. The -36% one-year return and high volatility profile appeal to options traders rather than long-term fundamental investors. Institutional ownership is minimal given unprofitability, small market cap, and regulatory uncertainty.
high - Cannabis stocks exhibit 2-3x market volatility with sharp moves on regulatory headlines, sector sentiment shifts, and liquidity events. Canopy's small float and retail-heavy shareholder base amplify price swings. The stock demonstrates low correlation with broader equity markets, instead tracking cannabis sector ETFs and US legalization speculation. Implied volatility typically ranges 80-120% versus 15-20% for S&P 500.
